33468 Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)

Roflumilast cream 0.3% is a selective and potent phosphodiesterase-4 inhibitor under investigation as a once-daily treatment for psoriasis. Psoriatic plaques on the knees/elbows can be challenging to treat due to thicker stratum corneum, which impedes topical absorption. We present pooled efficacy results from a post hoc analysis of the subgroup of patients with knee and/or elbow involvement from two identical phase 3 randomized controlled trials of roflumilast (DERMIS-1: NCT04211363 and DERMIS-2: NCT04211389).